{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:24:31Z","timestamp":1750526671252},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,6]],"date-time":"2014-10-06T00:00:00Z","timestamp":1412553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,10,6]],"date-time":"2014-10-06T00:00:00Z","timestamp":1412553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/bmt.2014.215","type":"journal-article","created":{"date-parts":[[2014,10,6]],"date-time":"2014-10-06T14:59:01Z","timestamp":1412607541000},"page":"82-86","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study"],"prefix":"10.1038","volume":"50","author":[{"given":"E","family":"Nikolousis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Nagra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kirkland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Dignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Tholouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gilleece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Littlewood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Peniket","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B E","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,6]]},"reference":[{"key":"BFbmt2014215_CR1","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878\u20131887.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014215_CR2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2003.09.110","volume":"21","author":"H Bertz","year":"2003","unstructured":"Bertz H, Potthoff K, Finke J . Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480\u20131484.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014215_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ajh.20990","volume":"82","author":"M Falda","year":"2007","unstructured":"Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B et al. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol 2007; 82: 863\u2013866.","journal-title":"Am J Hematol"},{"key":"BFbmt2014215_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bbmt.2011.07.013","volume":"18","author":"P Chevallier","year":"2012","unstructured":"Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant 2012; 18: 289\u2013294.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014215_CR5","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/cncr.21418","volume":"104","author":"DP Blaise","year":"2005","unstructured":"Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104: 1931\u20131938.","journal-title":"Cancer"},{"key":"BFbmt2014215_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","volume":"99","author":"R Chakraverty","year":"2002","unstructured":"Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071\u20131078.","journal-title":"Blood"},{"key":"BFbmt2014215_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.bbmt.2009.12.537","volume":"16","author":"J Koreth","year":"2010","unstructured":"Koreth J, Aldridge J, Kim HT, Alyea EP 3rd, Cutler C, Armand P et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 2010; 16: 792\u2013800.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014215_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bmt.2008.375","volume":"43","author":"RK Malladi","year":"2009","unstructured":"Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant 2009; 43: 709\u2013715.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014215_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/TP.0b013e3181e7a3bf","volume":"90","author":"B Carpenter","year":"2010","unstructured":"Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation 2010; 90: 564\u2013570.","journal-title":"Transplantation"},{"key":"BFbmt2014215_CR10","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","volume":"116","author":"R Chakraverty","year":"2010","unstructured":"Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010; 116: 3080\u20133088.","journal-title":"Blood"},{"key":"BFbmt2014215_CR11","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.23375","volume":"112","author":"M Sorror","year":"2008","unstructured":"Sorror M, Storer B, Sandmaier B, Maloney D, Chauncey T, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors or morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992\u20132001.","journal-title":"Cancer"},{"key":"BFbmt2014215_CR12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1001\/jama.2011.1558","volume":"306","author":"ML Sorror","year":"2011","unstructured":"Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 1874\u20131883.","journal-title":"JAMA"},{"key":"BFbmt2014215_CR13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/bmt.2011.138","volume":"47","author":"SW Bokhari","year":"2012","unstructured":"Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant 2012; 47: 528\u2013534.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014215_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/bmt.2009.236","volume":"45","author":"ZY Lim","year":"2010","unstructured":"Lim ZY, Ingram W, Brand R, Ho A, Kenyon M, Devereux S et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant 2010; 45: 633\u2013639.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014215_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/146532401753174025","volume":"3","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy 2001; 3: 197\u2013201.","journal-title":"Cytotherapy"},{"key":"BFbmt2014215_CR16","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","volume":"110","author":"E Olavarria","year":"2007","unstructured":"Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Post-transplant imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614\u20134617.","journal-title":"Blood"},{"key":"BFbmt2014215_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","volume":"103","author":"RD Faulkner","year":"2004","unstructured":"Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428\u2013434.","journal-title":"Blood"},{"key":"BFbmt2014215_CR18","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1182\/blood-2010-12-327536","volume":"118","author":"JC Marsh","year":"2011","unstructured":"Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351\u20132357.","journal-title":"Blood"},{"key":"BFbmt2014215_CR19","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014215_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.1977.1","volume":"35","author":"R Peto","year":"1977","unstructured":"Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1\u201339.","journal-title":"Br J Cancer"},{"key":"BFbmt2014215_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ . A proportional hazard models for the subdistribution of a competing risk. JASA 1999; 94: 496\u2013509.","journal-title":"JASA"},{"key":"BFbmt2014215_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1988; 16: 1141\u20131154.","journal-title":"Annals of Statistics"},{"key":"BFbmt2014215_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3324\/haematol.2009.013920","volume":"95","author":"C Craddock","year":"2010","unstructured":"Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantion for acute myeloid leukemia. Haematologica 2010; 95: 989\u2013995.","journal-title":"Haematologica"},{"key":"BFbmt2014215_CR24","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390\u20133400.","journal-title":"Blood"},{"key":"BFbmt2014215_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.bbmt.2010.02.004","volume":"16","author":"B Deschler","year":"2010","unstructured":"Deschler B, Binek K, Ihorst G, Marks R, Wasch R, Bertz H et al. Prognostic factor and quality of life analysis in 160 patients aged >or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16: 967\u2013975.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014215_CR26","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood.V88.8.3223.bloodjournal8883223","volume":"88","author":"D Mavroudis","year":"1996","unstructured":"Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223\u20133229.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2014215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014215","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:12:18Z","timestamp":1648059138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2014215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,6]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["BFbmt2014215"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2014.215","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,6]]},"assertion":[{"value":"18 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}